- Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer2023 | 1. lékařská fakulta
- Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma2021 | 1. lékařská fakulta
- Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone2021 | Publikace bez příslušnosti k fakultě
- Association of Selinexor Dose Reductions With Clinical Outcomes in the BOSTON Study2023 | 1. lékařská fakulta
- Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies2023 | 1. lékařská fakulta
- Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk2021 | 1. lékařská fakulta
- Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma2021 | 1. lékařská fakulta
- Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial2020 | 1. lékařská fakulta
- AML-Related NPM Mutations Drive p53 Delocalization into the Cytoplasm with Possible Impact on p53-Dependent Stress Response2021 | Matematicko-fyzikální fakulta
- Mnohočetný myelom - jsme schopni pacienta v roce 2020 vyléčit?2020 | 1. lékařská fakulta